177Lu-PNT2002

DRUG4 trials

Sponsors

Point Biopharma Inc., Glenn Bauman, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Adenoid Cystic CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Renal Cell CarcinomaMetastatic castration-resistant prostate cancer (mCRPC)Prostate Cancer

Phase 1

Radioligand fOr locAl raDiorecurrent proStaTe cancER

CompletedNCT05230251

Glenn BaumanProstate Cancer

Start: 2022-03-17End: 2024-12-31Updated: 2025-09-12

PSMA Therapy and Immunotherapy in Kidney Cancer

WithdrawnNCT06361810

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMetastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma

Start: 2025-10-01End: 2032-01-31Updated: 2025-08-19

Phase 2

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

TerminatedNCT06322576

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAdenoid Cystic Carcinoma

Start: 2025-02-10End: 2026-01-20Updated: 2026-01-22

Phase 3

SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment

Active, not recruitingCTIS2024-515604-39-00

Point Biopharma Inc.Metastatic castration-resistant prostate cancer (mCRPC)

Start: 2022-01-28Target: 65Updated: 2025-12-15

Related Papers

The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).

2023-04-207 citations